Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31, 2025, and related management discussion and analysis.... Read More

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher's disease. Sharp has launched its clinical development... Read More

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical-stage biotechnology company developing small molecule therapies to treat hereditary disorders, is pleased to announce that STX PARTNERS LLP (" STX ") and Newlin Investment Company (" NIC ") have each exercised their respective common share purchase warrants of... Read More

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, is pleased to announce the successful completion of its previously announced consolidation of its common shares (the " Common Shares ") on the basis of one (1)... Read More

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, announces that its board of directors has approved a consolidation (the " Consolidation ") of the Company's issued and outstanding common shares (the " Common Shares... Read More